Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while YieldMax NVDA Option Income Strategy ETF trades at $12.99. The key difference: YieldMax NVDA Option Income Strategy ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NVDY | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $491.22 | $17.96 |
52-Week Low | $205.48 | $11.58 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $13.06, up 2.59% today with a bullish technical signal. The ETF generates weekly dividend distributions through options strategies on NVIDIA stock, though recent news highlights concerns about opportunity cost versus direct NVIDIA ownership. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while moving averages remain bullish.
The outlook balances high income generation against capped upside potential. Investment opportunity lies in consistent weekly distributions, while primary risks include underperformance versus NVIDIA's explosive growth and the fund's strategy of selling call options that limit participation in NVIDIA's strongest rallies. The ETF appeals to income-focused investors willing to trade growth potential for regular cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
